思力华在稳定期慢性阻塞性肺疾病治疗中的应用

Application of Spiriva in Treatment of Chronic Obstructive Pulmonary Disease in Stable Phase

目的探讨思力华在稳定期慢性阻塞性肺疾病治疗中的应用效果。方法整群选取2011年6月—2015年1月医院确诊的慢性阻塞性肺疾病患者298例,随机分成两组各149例,对照组给予氨茶碱,观察组给予思力华,比较两组的肺功能指标和不良反应。结果观察组治疗后肺功能上升指数明显优于对照组(P<0.05),观察组不良反应发生率为3.3%,对照组不良反应发生率为10.7%,比较差异有统计学意义(P<0.05)。结论思力华治疗稳定期慢性阻塞性肺疾病临床疗效显著,值得应用。

Objective To discuss the application effect of spiriva in treatment of chronic obstructive pulmonary disease in stable phase. Methods 298 cases of patients with chronic obstructive pulmonary disease diagnosed in our hospital from June 2011 to January 2015 were selected and randomly divided into two groups with 149 cases in each, the control group were treated with aminophylline, the observation group were treated with spiriva, the lung function indexes and adverse reactions were compared between the two groups. Results The lung function rising index in the observation group was obviously better than that in the control group after treatment, P〈0.05, the difference in the incidence rate of adverse reactions between the observation group and the control group was statistically significant by comparison 3.3% vs 10.7%, P 〈0.05.Conclusion The clinical curative effect of spiriva in treatment of chronic obstructive pulmonary disease in stable phase is obvious, which is worth promotion.